In the Point-Counterpoint Review on the advantages of GEMs over xenografts in the April 1, 2006 issue of Cancer Research (1), reference 19 should have read as follows:

19. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004;10:1257–60.

1
Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies.
Cancer Res
2006
;
66
:
3355
–9.